Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jan;35(1):4-11.
doi: 10.2337/dc11-0931. Epub 2011 Oct 31.

Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes

Jody Dushay  1 , Chuanyun Gao, Gosala S Gopalakrishnan, Meghan Crawley, Emilie K Mitten, Elissa Wilker, Janet Mullington, Eleftheria Maratos-Flier
Affiliations
Randomized Controlled Trial

Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes

Jody Dushay et al. Diabetes Care. 2012 Jan.

Abstract

Objective: To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women.

Research design and methods: Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight.

Results: Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A total of 30% of subjects were high responders who lost ≥5% body weight (-7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (-2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%). Waist circumference also decreased significantly with exenatide treatment. Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss.

Conclusions: Short-term exenatide treatment was associated with modest weight loss and decreased waist circumference in a cohort of obese nondiabetic women. A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: Change in body weight during exenatide and placebo treatment periods. Error bars represent ± SEM. P < 0.02 at 2 weeks. B: Individual weight profiles during exenatide treatment among high responders (n = 11). C: Individual weight profiles during exenatide treatment among moderate responders (n = 14). D: Individual weight profiles during exenatide treatment among nonresponders (n = 12).
Figure 1
Figure 1
A: Change in body weight during exenatide and placebo treatment periods. Error bars represent ± SEM. P < 0.02 at 2 weeks. B: Individual weight profiles during exenatide treatment among high responders (n = 11). C: Individual weight profiles during exenatide treatment among moderate responders (n = 14). D: Individual weight profiles during exenatide treatment among nonresponders (n = 12).
Figure 1
Figure 1
A: Change in body weight during exenatide and placebo treatment periods. Error bars represent ± SEM. P < 0.02 at 2 weeks. B: Individual weight profiles during exenatide treatment among high responders (n = 11). C: Individual weight profiles during exenatide treatment among moderate responders (n = 14). D: Individual weight profiles during exenatide treatment among nonresponders (n = 12).
Figure 1
Figure 1
A: Change in body weight during exenatide and placebo treatment periods. Error bars represent ± SEM. P < 0.02 at 2 weeks. B: Individual weight profiles during exenatide treatment among high responders (n = 11). C: Individual weight profiles during exenatide treatment among moderate responders (n = 14). D: Individual weight profiles during exenatide treatment among nonresponders (n = 12).
See this image and copyright information in PMC

References

    1. Glant M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes 2011;2011:636181. - PMC - PubMed
    1. Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med 2010;153:147–157 - PMC - PubMed
    1. Shai I, Schwarzfuchs D, Henkin Y, et al. ; Dietary Intervention Randomized Controlled Trial (DIRECT) Group Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359:229–241 - PubMed
    1. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859–873 - PMC - PubMed
    1. Barte JCM, ter Bogt NCW, Bogers RP, et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev 2010;11:899–906 - PubMed

Publication types